Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
NXP Semiconductors
NXPI
US Stock MarketDetailed Quotes
Cognition Therapeutics (CGTX)
- 0.9608
- +0.0208+2.21%
Close Jul 17 16:00 ET
- 0.9500
- -0.0108-1.12%
Post 20:01 ET
85.99MMarket Cap-4.18P/E (TTM)
0.9837High0.9201Low468.03KVolume0.9433Open0.9400Prev Close448.66KTurnover0.57%Turnover RatioLossP/E (Static)89.50MShares3.830052wk High2.88P/B78.62MFloat Cap0.550152wk Low--Dividend TTM81.83MShs Float13.8000Historical High--Div Yield TTM6.77%Range %0.2223Historical Low0.9586Avg Price1Lot Size
CGTX Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
CGTX Orderflow
Unit: --
CGTX Orderflow Trend
IntradayDayWeekMonth
No Data
Cognition Therapeutics (CGTX) News
Buy Rating Reaffirmed on Accelerating LIBERTY System Traction; $12 Price Target Maintained
Cognition Therapeutics CEO Lisa Ricciardi to Participate in B. Riley Mind, Muscle & Vision Summit Fireside Discussion
Analysts Are Bullish on These Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Akebia Therapeutics (AKBA)
We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
H.C. Wainwright Keeps Their Buy Rating on Cognition Therapeutics (CGTX)
12 Health Care Stocks Moving In Wednesday's Intraday Session
Cognition Therapeutics (CGTX) Stock Forum
$Cognition Therapeutics (CGTX.US)$ anybody home?
$Cognition Therapeutics (CGTX.US)$ what a nightmare
3
$Cognition Therapeutics (CGTX.US)$
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
by Globe Newswire
Follow
- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease -
- Company Developing NPI as a Measure of DLB Psychosis -
PURCHASE, N.Y., June 24, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CG...
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
by Globe Newswire
Follow
- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease -
- Company Developing NPI as a Measure of DLB Psychosis -
PURCHASE, N.Y., June 24, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CG...
2
$Cognition Therapeutics (CGTX.US)$ Cognition Therapeutics Receives Notice Of Allowance From USPTO For Patent Application 19/563,468, Covering Polymorphic Crystalline Form Of Zervimesine
Benzinga
1m
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/5...
Benzinga
1m
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/5...
$Cognition Therapeutics (CGTX.US)$ im new here. should i buy 100 or should i go elsewhere?
1
Read more
Market Insights
Hot AI Stocks Hot AI Stocks
AI stocks surge on chip demand and cloud security breakthroughs; future growth hinges on autonomous driving and global computing infrastructure AI stocks surge on chip demand and cloud security breakthroughs; future growth hinges on autonomous driving and global computing infrastructure